Symbols / CVRX
CVRX Chart
About
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular system to the autonomic nervous system. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Devices | Market Cap | 190.50M |
| Enterprise Value | 165.29M | Income | -53.31M | Sales | 56.65M |
| Book/sh | 1.50 | Cash/sh | 2.88 | Dividend Yield | — |
| Payout | 0.00% | Employees | 223 | IPO | — |
| P/E | — | Forward P/E | -4.07 | PEG | — |
| P/S | 3.36 | P/B | 4.84 | P/C | — |
| EV/EBITDA | -3.27 | EV/Sales | 2.92 | Quick Ratio | 6.49 |
| Current Ratio | 7.63 | Debt/Eq | 128.43 | LT Debt/Eq | — |
| EPS (ttm) | -2.04 | EPS next Y | -1.78 | EPS Growth | — |
| Revenue Growth | 4.40% | Earnings | 2026-05-14 | ROA | -26.90% |
| ROE | -96.59% | ROIC | — | Gross Margin | 85.33% |
| Oper. Margin | -69.80% | Profit Margin | -94.10% | Shs Outstand | 26.31M |
| Shs Float | 17.20M | Short Float | 8.48% | Short Ratio | 4.51 |
| Short Interest | — | 52W High | 14.04 | 52W Low | 4.30 |
| Beta | 1.28 | Avg Volume | 291.77K | Volume | 639.13K |
| Target Price | $11.17 | Recom | Buy | Prev Close | $6.79 |
| Price | $7.24 | Change | 6.63% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$11.17
Mean price target
2. Current target
$7.24
Latest analyst target
3. DCF / Fair value
$-16.27
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$7.24
Low
$6.00
High
$14.00
Mean
$11.17
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-13 | main | Canaccord Genuity | Buy → Buy | $10 |
| 2025-11-06 | main | Canaccord Genuity | Buy → Buy | $11 |
| 2025-11-06 | main | Cantor Fitzgerald | Overweight → Overweight | $13 |
| 2025-08-05 | reit | Cantor Fitzgerald | Overweight → Overweight | $11 |
| 2025-05-09 | main | Piper Sandler | Overweight → Overweight | $12 |
| 2025-05-09 | down | JP Morgan | Neutral → Underweight | $7 |
| 2025-04-08 | main | Lake Street | Buy → Buy | $14 |
| 2025-04-08 | main | Canaccord Genuity | Buy → Buy | $18 |
| 2025-02-05 | main | Piper Sandler | Overweight → Overweight | $20 |
| 2025-02-05 | main | Canaccord Genuity | Buy → Buy | $23 |
| 2025-01-17 | main | Craig-Hallum | Buy → Buy | $22 |
| 2025-01-14 | up | William Blair | Market Perform → Outperform | — |
| 2024-12-09 | main | Canaccord Genuity | Buy → Buy | $22 |
| 2024-11-04 | main | Craig-Hallum | Buy → Buy | $20 |
| 2024-10-30 | main | Lake Street | Buy → Buy | $15 |
| 2024-10-30 | main | Canaccord Genuity | Buy → Buy | $17 |
| 2024-10-30 | reit | Piper Sandler | Overweight → Overweight | $16 |
| 2024-10-23 | reit | Cantor Fitzgerald | Overweight → Overweight | $14 |
| 2024-09-10 | init | Cantor Fitzgerald | — → Overweight | $14 |
| 2024-08-26 | reit | Lake Street | Buy → Buy | $12 |
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX - FinancialContent ue, 24 Feb 2026 22
- $CVRX stock is up 9% today. Here's what we see in our data. - Quiver Quantitative Mon, 23 Feb 2026 19
- (CVRX) and the Role of Price-Sensitive Allocations - Stock Traders Daily ue, 24 Feb 2026 02
- CVRx Insider Makes Bold Move With Fresh Share Purchase - TipRanks Mon, 23 Feb 2026 08
- Earnings call transcript: CVRx Q4 2025 sees stock surge despite earnings miss - Investing.com Nigeria Sat, 21 Feb 2026 06
- CVRx’s stock up as heart failure device to be trialled in expanded patient group - Medical Device Network Fri, 23 Jan 2026 08
- Monday 2/23 Insider Buying Report: MPLT, CVRX - Nasdaq Mon, 23 Feb 2026 18
- Insider Purchase: Director at $CVRX Buys 46,800 Shares - Quiver Quantitative Mon, 23 Feb 2026 11
- CVRx (CVRX) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance hu, 12 Feb 2026 08
- Securities Fraud Investigation Into CVRx, Inc. (CVRX) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz - The AI Journal hu, 19 Feb 2026 19
- Analysts Are Updating Their CVRx, Inc. (NASDAQ:CVRX) Estimates After Its Full-Year Results - Sahm Sun, 15 Feb 2026 08
- Canaccord Genuity lowers CVRx stock price target to $10 on sector multiple decline - Investing.com Nigeria Fri, 13 Feb 2026 08
- Insider Stock Purchases: February 23, 2026 - Quiver Quantitative Mon, 23 Feb 2026 18
- CVRx stock rises after announcing major heart failure clinical trial - Investing.com hu, 22 Jan 2026 08
- $CVRX stock is down 14% today. Here's what we see in our data. - Quiver Quantitative ue, 13 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 46800 | 297592 | — | Purchase at price 6.36 per share. | JAIN MUDIT KUMAR | Director | — | 2026-02-20 00:00:00 | I |
| 1 | 600 | 2785 | — | Purchase at price 4.64 per share. | JAIN MUDIT KUMAR | Director | — | 2026-02-18 00:00:00 | D |
| 2 | 6337 | 63560 | — | Sale at price 10.03 per share. | JOHNSON & JOHNSON | Beneficial Owner of more than 10% of a Class of Security | — | 2025-11-26 00:00:00 | I |
| 3 | 22337 | 224040 | — | Sale at price 10.03 per share. | JOHNSON & JOHNSON | Beneficial Owner of more than 10% of a Class of Security | — | 2025-11-26 00:00:00 | I |
| 4 | 2700 | 27132 | — | Sale at price 10.00 - 10.06 per share. | JOHNSON & JOHNSON | Beneficial Owner of more than 10% of a Class of Security | — | 2025-11-24 00:00:00 | I |
| 5 | 1000 | 10000 | — | Sale at price 10.00 per share. | JOHNSON & JOHNSON | Beneficial Owner of more than 10% of a Class of Security | — | 2025-11-12 00:00:00 | I |
| 6 | 1000 | 10000 | — | Sale at price 10.00 per share. | JOHNSON & JOHNSON DEVELOPMENT CORPORATION | Beneficial Owner of more than 10% of a Class of Security | — | 2025-11-12 00:00:00 | I |
| 7 | 52532 | 536310 | — | Sale at price 10.00 - 10.21 per share. | JOHNSON & JOHNSON INNOVATION - JJDC, INC. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-11-07 00:00:00 | I |
| 8 | 16600 | — | — | Stock Award(Grant) at price 0.00 per share. | BINKOWSKI BRENT | Chief Operating Officer | — | 2025-08-11 00:00:00 | D |
| 9 | 10966 | 59795 | — | Purchase at price 5.45 per share. | NIELSEN KIRK G | Director | — | 2025-05-15 00:00:00 | I |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.21 | 0.21 | 0.21 |
| NormalizedEBITDA | -46.74M | -54.89M | -38.73M | -40.74M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -53.31M | -59.97M | -41.20M | -41.43M |
| ReconciledDepreciation | 756.00K | 619.00K | 522.00K | 412.00K |
| ReconciledCostOfRevenue | 8.31M | 8.33M | 6.26M | 5.00M |
| EBITDA | -46.74M | -54.89M | -38.73M | -40.74M |
| EBIT | -47.50M | -55.51M | -39.25M | -41.15M |
| NetInterestIncome | -5.83M | -4.40M | -1.80M | -165.00K |
| InterestExpense | 5.83M | 4.40M | 1.80M | 165.00K |
| NormalizedIncome | -53.31M | -59.97M | -41.20M | -41.43M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -53.31M | -59.97M | -41.20M | -41.43M |
| TotalExpenses | 107.92M | 110.78M | 82.40M | 65.00M |
| TotalOperatingIncomeAsReported | -51.27M | -59.49M | -43.10M | -42.53M |
| DilutedAverageShares | 26.08M | 22.60M | 20.75M | 20.53M |
| BasicAverageShares | 26.08M | 22.60M | 20.75M | 20.53M |
| DilutedEPS | -2.04 | -2.65 | -1.99 | -2.02 |
| BasicEPS | -2.04 | -2.65 | -1.99 | -2.02 |
| DilutedNIAvailtoComStockholders | -53.31M | -59.97M | -41.20M | -41.43M |
| NetIncomeCommonStockholders | -53.31M | -59.97M | -41.20M | -41.43M |
| NetIncome | -53.31M | -59.97M | -41.20M | -41.43M |
| NetIncomeIncludingNoncontrollingInterests | -53.31M | -59.97M | -41.20M | -41.43M |
| NetIncomeContinuousOperations | -53.31M | -59.97M | -41.20M | -41.43M |
| TaxProvision | -18.00K | 55.00K | 147.00K | 109.00K |
| PretaxIncome | -53.32M | -59.91M | -41.05M | -41.32M |
| OtherIncomeExpense | 3.77M | 3.98M | 3.85M | 1.37M |
| OtherNonOperatingIncomeExpenses | 3.77M | 3.98M | 3.85M | 1.37M |
| NetNonOperatingInterestIncomeExpense | -5.83M | -4.40M | -1.80M | -165.00K |
| InterestExpenseNonOperating | 5.83M | 4.40M | 1.80M | 165.00K |
| OperatingIncome | -51.27M | -59.49M | -43.10M | -42.53M |
| OperatingExpense | 99.61M | 102.45M | 76.14M | 60.00M |
| ResearchAndDevelopment | 11.13M | 11.13M | 11.63M | 9.95M |
| SellingGeneralAndAdministration | 88.47M | 91.32M | 64.51M | 50.05M |
| GrossProfit | 48.34M | 42.96M | 33.04M | 17.47M |
| CostOfRevenue | 8.31M | 8.33M | 6.26M | 5.00M |
| TotalRevenue | 56.65M | 51.29M | 39.30M | 22.47M |
| OperatingRevenue | 56.65M | 51.29M | 39.30M | 22.47M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 26.31M | 25.32M | 20.88M | 20.63M |
| ShareIssued | 26.31M | 25.32M | 20.88M | 20.63M |
| TotalDebt | 50.50M | 50.43M | 30.61M | 7.09M |
| TangibleBookValue | 39.32M | 71.06M | 75.95M | 109.18M |
| InvestedCapital | 88.84M | 120.33M | 105.17M | 115.93M |
| WorkingCapital | 88.33M | 119.05M | 104.23M | 114.79M |
| NetTangibleAssets | 39.32M | 71.06M | 75.95M | 109.18M |
| CapitalLeaseObligations | 990.00K | 1.16M | 1.39M | 339.00K |
| CommonStockEquity | 39.32M | 71.06M | 75.95M | 109.18M |
| TotalCapitalization | 88.84M | 120.33M | 105.17M | 115.93M |
| TotalEquityGrossMinorityInterest | 39.32M | 71.06M | 75.95M | 109.18M |
| StockholdersEquity | 39.32M | 71.06M | 75.95M | 109.18M |
| GainsLossesNotAffectingRetainedEarnings | -203.00K | -206.00K | -207.00K | -207.00K |
| OtherEquityAdjustments | -203.00K | -206.00K | -207.00K | -207.00K |
| RetainedEarnings | -590.65M | -537.35M | -477.38M | -436.18M |
| AdditionalPaidInCapital | 629.92M | 608.35M | 553.33M | 545.36M |
| CapitalStock | 263.00K | 253.00K | 209.00K | 207.00K |
| CommonStock | 263.00K | 253.00K | 209.00K | 207.00K |
| TotalLiabilitiesNetMinorityInterest | 65.47M | 62.36M | 39.28M | 15.76M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 52.15M | 51.60M | 31.42M | 7.67M |
| OtherNonCurrentLiabilities | 2.00M | 1.45M | 1.04M | 805.00K |
| PreferredSecuritiesOutsideStockEquity | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 50.15M | 50.15M | 30.38M | 6.86M |
| LongTermCapitalLeaseObligation | 638.00K | 877.00K | 1.16M | 117.00K |
| LongTermDebt | 49.51M | 49.27M | 29.22M | 6.75M |
| CurrentLiabilities | 13.32M | 10.76M | 7.86M | 8.09M |
| CurrentDebtAndCapitalLeaseObligation | 352.00K | 282.00K | 231.00K | 222.00K |
| CurrentCapitalLeaseObligation | 352.00K | 282.00K | 231.00K | 222.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 6.97M | 5.67M | 4.11M | 3.26M |
| PayablesAndAccruedExpenses | 6.00M | 4.81M | 3.53M | 4.60M |
| CurrentAccruedExpenses | 2.07M | 2.09M | 1.52M | 2.76M |
| InterestPayable | 403.00K | 437.00K | 220.00K | 0.00 |
| Payables | 3.93M | 2.72M | 2.01M | 1.84M |
| TotalTaxPayable | 93.00K | 135.00K | 125.00K | 120.00K |
| AccountsPayable | 3.83M | 2.58M | 1.88M | 1.72M |
| TotalAssets | 104.79M | 133.41M | 115.23M | 124.94M |
| TotalNonCurrentAssets | 3.15M | 3.60M | 3.14M | 2.06M |
| OtherNonCurrentAssets | 26.00K | 27.00K | 27.00K | 27.00K |
| NetPPE | 3.12M | 3.57M | 3.11M | 2.03M |
| AccumulatedDepreciation | -4.15M | -3.41M | -2.79M | -2.28M |
| GrossPPE | 7.27M | 6.98M | 5.90M | 4.31M |
| Leases | 827.00K | 542.00K | 98.00K | 95.00K |
| ConstructionInProgress | 325.00K | 720.00K | 554.00K | 231.00K |
| OtherProperties | 4.41M | 4.21M | 4.07M | 3.02M |
| MachineryFurnitureEquipment | 1.71M | 1.51M | 1.18M | 968.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 101.65M | 129.81M | 112.09M | 122.88M |
| OtherCurrentAssets | 3.07M | 2.50M | 2.99M | 4.22M |
| PrepaidAssets | 2.58M | |||
| Inventory | 12.21M | 12.11M | 10.98M | 6.96M |
| FinishedGoods | 3.10M | 4.90M | 5.62M | 3.53M |
| WorkInProcess | 473.00K | 353.00K | 654.00K | 1.03M |
| RawMaterials | 8.63M | 6.86M | 4.71M | 2.39M |
| Receivables | 10.66M | 9.27M | 7.55M | 5.50M |
| AccountsReceivable | 10.66M | 9.27M | 7.55M | 5.50M |
| AllowanceForDoubtfulAccountsReceivable | -871.00K | -780.00K | -508.00K | -679.00K |
| GrossAccountsReceivable | 11.54M | 10.05M | 8.06M | 6.18M |
| CashCashEquivalentsAndShortTermInvestments | 75.71M | 105.93M | 90.57M | 106.19M |
| CashAndCashEquivalents | 75.71M | 105.93M | 90.57M | 106.19M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -40.75M | -40.51M | -39.61M | -43.36M |
| RepurchaseOfCapitalStock | 0.00 | -1.00K | ||
| RepaymentOfDebt | 0.00 | -21.30M | ||
| IssuanceOfDebt | 0.00 | 20.00M | 22.50M | 7.50M |
| IssuanceOfCapitalStock | 8.97M | 32.52M | 0.00 | 0.00 |
| CapitalExpenditure | -580.00K | -1.36M | -591.00K | -685.00K |
| InterestPaidSupplementalData | 5.04M | 3.61M | 1.40M | 59.00K |
| IncomeTaxPaidSupplementalData | 0.00 | 4.00K | 5.00K | 2.00K |
| EndCashPosition | 75.71M | 105.93M | 90.57M | 106.19M |
| BeginningCashPosition | 105.93M | 90.57M | 106.19M | 142.07M |
| EffectOfExchangeRateChanges | 5.00K | -1.00K | 3.00K | -9.00K |
| ChangesInCash | -30.23M | 15.37M | -15.63M | -35.87M |
| FinancingCashFlow | 10.52M | 55.87M | 23.98M | 7.49M |
| CashFlowFromContinuingFinancingActivities | 10.52M | 55.87M | 23.98M | 7.49M |
| NetOtherFinancingCharges | -152.00K | -179.00K | -778.00K | |
| ProceedsFromStockOptionExercised | 1.55M | 3.50M | 1.66M | 771.00K |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 8.97M | 32.52M | 0.00 | 0.00 |
| CommonStockPayments | 0.00 | -1.00K | ||
| CommonStockIssuance | 8.97M | 32.52M | 0.00 | 0.00 |
| NetIssuancePaymentsOfDebt | 0.00 | 20.00M | 22.50M | 7.50M |
| NetLongTermDebtIssuance | 0.00 | 20.00M | 22.50M | 7.50M |
| LongTermDebtPayments | 0.00 | -21.30M | ||
| LongTermDebtIssuance | 0.00 | 20.00M | 22.50M | 7.50M |
| InvestingCashFlow | -580.00K | -1.36M | -591.00K | -685.00K |
| CashFlowFromContinuingInvestingActivities | -580.00K | -1.36M | -591.00K | -685.00K |
| NetPPEPurchaseAndSale | -580.00K | -1.36M | -591.00K | -685.00K |
| PurchaseOfPPE | -580.00K | -1.36M | -591.00K | -685.00K |
| OperatingCashFlow | -40.17M | -39.14M | -39.02M | -42.68M |
| CashFlowFromContinuingOperatingActivities | -40.17M | -39.14M | -39.02M | -42.68M |
| ChangeInWorkingCapital | 1.00M | 949.00K | -4.80M | -5.57M |
| ChangeInPayablesAndAccruedExpense | 3.04M | 3.26M | -5.00K | 2.08M |
| ChangeInAccruedExpense | 1.79M | 2.56M | -170.00K | 873.00K |
| ChangeInPayable | 1.25M | 698.00K | 165.00K | 1.21M |
| ChangeInAccountPayable | 1.25M | 698.00K | 165.00K | 1.21M |
| ChangeInPrepaidAssets | -543.00K | 531.00K | 1.27M | -1.63M |
| ChangeInInventory | -98.00K | -1.12M | -4.03M | -3.08M |
| ChangeInReceivables | -1.40M | -1.72M | -2.05M | -2.94M |
| ChangesInAccountReceivables | -1.40M | -1.72M | -2.05M | -2.94M |
| OtherNonCashItems | 241.00K | 203.00K | 154.00K | 25.00K |
| StockBasedCompensation | 11.05M | 19.05M | 6.30M | 3.89M |
| DepreciationAmortizationDepletion | 756.00K | 619.00K | 522.00K | 412.00K |
| DepreciationAndAmortization | 756.00K | 619.00K | 522.00K | 412.00K |
| Depreciation | 756.00K | 619.00K | 522.00K | 412.00K |
| OperatingGainsLosses | 86.00K | 4.00K | 14.62M | |
| GainLossOnInvestmentSecurities | 13.29M | |||
| GainLossOnSaleOfPPE | 86.00K | 0.00 | 4.00K | 0.00 |
| NetIncomeFromContinuingOperations | -53.31M | -59.97M | -41.20M | -41.43M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CVRX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|